IGF-1 is known to activate the canonic Wnt/β-catenin signaling pathway,
12 leading to inactivation of GSK-3β and dephosphorylation of β-catenin in the cytoplasm and translocation of β-catenin into the cells’ nuclei. As a consequence, a decrease in β-catenin and GSK-3β transcription and translation can be observed, which was confirmed by our data. At its end, this signal transduction pathway is initiating the transcription of target genes as cyclin D1,
19 the main marker of the G
1-phase of the cell cycle. Cyclin D1 proteolysis and subcellular localization is known to be regulated by GSK-3β.
20 As subcellular distribution of cyclin D1 is cell-cycle dependent, it accumulates in the nuclei of cells in the G
1-phase and exits the nucleus during S-phase,
21 resulting in an increase in cyclin D1 during G
1 and a decrease in the late G
1- and S-phases. Our cytometry data confirmed an increase in cyclin D1 protein in the cytoplasm of cells due to the induction of proliferation via activation of the β-catenin signaling pathway. In parallel, we measured a decrease in cyclin D1 mRNA transcription in the cells’ nuclei, as with this boost in proliferation, the cells passed the G
1 restriction point and headed forward into the S-G
2/M-phase of the cell cycle, where other cyclin-dependent kinases (i.e., cyclin E) bestride the cell cycle. Our cell cycle analyses confirmed this progress of cells into the active cell cycle, pointing out an increase in cells entering the S-G
2/M-phase accompanied by a decrease in cells cycling at the G
1 stage. Therefore, we investigated the downregulation of cyclin D1 transcription while the amount of cyclin D1 protein in the cytoplasm was still high. In addition we observed a decrease in the differentiation markers RPE65, CRALBP, and the cytoskeleton marker cytokeratin on the transcriptional and translational levels, highlighting the upregulation of cell proliferation after activation of the β-catenin signaling pathway via IGF-1 treatment. Our control experiments indicated that differentiation/cytoskeleton markers of RPE cells usually are already expressed at low levels during the proliferative phase of cells. However, induction of proliferation by growth factor treatment further reduced expression from this low level. One might speculate that this effect is even stronger in fully mature RPE cells.